Introduction
Atherosclerosis and its sequelae are the most frequent cause of death in Western societies. The continuing age-related narrowing of (coronary) arteries can necessitate the need for percutaneous transluminal angioplasty. The long-term effects of such therapy, however, are still limited by an excessive arterial remodeling and restenosis 1, 2 .
We have previously shown that extracellular RNA (eRNA) can exert prothrombotic and inflammatory properties in the vasculature. eRNA functions as a cofactor in protease autoactivation of contact-phase coagulation factors 3, 4 and of Vascular Endothelial Growth factor (VEGF)-and VEGF-receptor2-coupled signaling pathways 5, 6 and may induce cytokine mobilization and liberation from inflammatory cells 7 . Moreover, systemic treatment with
RNase1 was shown to rescue mice from arterial thrombotic occlusion, to limit cerebral edema and infarct size after acute stroke, and to serve as a potent anti-inflammatory regimen in vitro and in vivo 3, 5, [7] [8] [9] .
Based on these previous results and the contribution of eRNA to inflammatory processes, we have here investigated the role of eRNA in high-fat-diet induced atherosclerosis in low density lipoprotein receptor-deficient (Ldlr -/-) mice and in a model of accelerated plaque formation in carotid arteries after injury in apolipoprotein E-deficient (apoE -/-) mice.
Our new data provide strong evidence that eRNA-mediated reactions contribute to inflammationdriven processes in experimental atherosclerosis and vascular remodeling and that administration of RNase1 serves as a new intervention modality for the protection from atherogenesis.
Methods

Mouse models of atherosclerosis and intravital microscopy
Wild-type and Ldlr -/-mice (both on the C57BL/6J background, n=6 per group) were obtained mobilization and liberation from inflammatory cells 7 . Moreover, systemic treatm me ment nt nt w w wit it ith h h RNase1 was shown to rescue mice from arterial thrombotic occlusion, to limit cerebral edema an nd d d in in infa fa farc rc ct t t si siz z ze a a aft ft fter er acute stroke, and to serve a a as s s a a poten t t anti-inf nf fla l mm mm ma at atory regimen in vitro an nd d d in i vivo 3, 3 5, 5, 7-9 7-9 -9 .
Ba Base se sed d d on on th he hese se e p p pre revi vio ou ous s s re re resu su sult lts s s an an and d d t th the e e co co ont nt tri r b bu buti ti tion on on o o of f f eR eR RNA NA NA t t to in infl fl flam am amma ma ato to ory ry y pr ro roce ce ess ses e , we have here e i i inv nv nves es esti ti tiga ga gate te ted th th the e e ro o ole le le o o of f f eR eR RNA NA NA i i in n n h h hig ig igh-h-h fa fa f t-t-di di d et et et i i ind nd nduc uc u ed ed d n n at at athe he hero ro rosc sc s le le ero ro rosi si sis s s in in i low from the Jackson Laboratory (Bar Harbor, ME, USA), and apoE -/-mice (C57BL/6J background, n=13-14 per group) from Charles River, Italy. Ldlr -/-mice were fed an atherogenic diet as described 10 . ApoE -/-mice, placed on an atherogenic high fat diet (HFD, 21% fat, 0.15% cholesterol) for one week before and up to three weeks after injury, were anaesthetized (100 mg/kg ketamine hydrochloride/ 10 mg/kg xylazine i.p.) and subjected to wire-induced arterial injury of the common carotid artery, as described 11, 12 . Animals were treated intravenously with a bolus of 0.76 μg RNase1 (in PBS) or PBS alone immediately before arterial injury, and continuously treated with RNase1 via Alzet ® osmotic minipumps (42 μg/kg mouse per day), subcutaneously implanted one day before injury. Intravital microscopy was performed one day after injury as described 11 . All animal studies were approved by local authorities and complied with German animal protection law.
Immunohistochemistry and quantification of RNA
5μm-thick cryosections of aortic sinus from Ldlr -/-mice were used for RNA localization by staining with SYTO® RNASelect™ dye (Invitrogen) 3 and visualizing with confocal microscopy (Nikon Eclipse TE2000-E, Nikon, Japan). Carotid arteries of apoE -/-mice were excised and embedded in paraffin. Neointimal and medial areas were quantified in serial sections within 500 μm from the bifurcation by modified Movat's pentachrome staining and planimetry. Adjacent sections were used to assess cellular plaque content by immunofluorescence staining of Mac2 + macrophages and -SMA + SMC 12 . For quantification of RNA, sections stained for SMC with TRITC-labeled antibody against smooth muscle -actin, SYTO® RNASelect™ dye and DAPI were examined by laser scanning confocal microscopy (Leica TCS SP2). Each independent experiment represents the mean value of ten randomly chosen fields of vision in each section, quantified using three-dimensional "Quantification" and "VoxelShop" options of Imaris 6.3.1 after injury as described 11 . All animal studies were approved by local authorities s a and nd nd c c com om ompl pl plie ie ied d
with German animal protection law. Nikon Eclip ip pse se se T T TE2 E2 E200 00 000-0-0 E, E, , N N Nik ik i on on on, , Ja Ja Japa a an) n) n). Ca Ca Caro ro roti ti id d d ar ar rte teri ri ies es es o o of f f ap ap apoE oE o (Bitplane). The area of specific labeling for eRNA was separately calculated as arbitrary fluorescent units of positive labeling per medial area or neointimal area, as previously described 13 .
RNase activity
At indicated time points, blood was taken from mice for analysis of RNase1 activity by an enzymatic assay, as described 8 . All activity values were normalized to the same protein concentration in different samples.
Isolation of eRNA and real time PCR analysis
DNA-free total RNA was extracted from serum of mice or cultured cell supernatants using the Zymo RNA MicroPrep kit (Zymo Research), including an additional DNA-digestion step. For real time PCR analysis, RNA was reverse-transcribed into cDNA at 37°C for 1 h (BioAnalyzer), and cDNA fragments were amplified using specific primer pairs (see Online Data Supplement for details).
Cell culture and cell adhesion assay under flow
Bone marrow-derived macrophages (BMDM) were generated from bone marrow cells in M-CSF-containing L929-conditioned medium as described 10, 14 , or by incubation with mouse recombinant M-CSF or GM-CSF (50ng/ml each) 15 . Experiments were carried out for 24 h in 6-well trays (1.5 x 10 6 cells/ml; Costar, Cambridge, MA) in the absence or presence of eRNA (1, 10 or 25 μg/ml), as indicated. Control cells were treated with growth medium alone (vehicle).
For quantitation of TNF-and Interleukin (IL)-6 protein production, BMDM were treated with eRNA (1, 10 or 25 μg/ml) for 24 h, followed by centrifugation and concentration of cell supernatants using centricon tubes (Millipore, Frankfurt, Germany) with a cutoff at 10 kDa.
TNF-and IL-6 ELISA were performed using commercially available kits from eBioscience MonoMac6 cells were maintained, as described 11, 16 . MonoMac6 cell adhesion to SMC was analyzed in parallel wall flow-chambers 11 . Confluent SMC were activated with eRNA (1, 10 or 25 μg/ml), or TNF-(50 ng/ml) in the absence or presence of RNase1 (10 μg/ml) for 16 h.
Viability assay
Viability assays were performed after treating SMC and MonoMac6 cells with RNase1 (10 μg/ml) for 30 min or 16 h using the fluorescent CellTiter-Blue ® cell viability assay (Promega, Mannheim, Germany).
Statistics
Data were analyzed by unpaired Student t tests or ANOVA 1-way analysis of variance followed by Tukey's or Dunnett's multiple comparison post-tests (detailed in the online Data Supplement).
Differences with p<0.05 were considered to be statistically significant. We further assessed RNA-degrading RNase activity in plasma samples from these mice during the course of HFD-feeding, and observed a biphasic characteristic with a temporary increase during the first 2 weeks (44 9 vs. 70 7 mU/mg protein; p=0.0012), followed by a significant and sustained decrease to about 20-40% of the activity in baseline controls, starting at 4 weeks of HFD-feeding (44 9 vs. 12 2 mU/mg protein; p 0.0001) ( Figure 2L ).
Results
eRNA accumulates within lesions whereas plasma RNase activity decreases with the progression of atherosclerosis
These data indicate that plasma RNase activity is enhanced in early atherosclerosis, but decreases during further plaque growth, when eRNA accumulates within atherosclerotic lesions in a time-progressive manner. Figure 1) . In accordance with our proposal, these data clearly corroborate that self-eRNA serves as an pro-inflammatory alarming signal.
Accordingly, the release of TNF-and IL-6 proteins into the cell supernatants was significantly increased by eRNA stimulation in a concentration-dependent manner ( Figure   3C ,D). We furthermore assessed whether these effects were mediated by eRNA-induced Tolllike receptor (TLR)-mediated signaling. Based on findings that no changes in Stat1 expression were found in macrophages upon stimulation with eRNA ( Figure 3A , B, and Supplementary   Figure 1) , we can conclude that eRNA does not engage in TLR-2 and TLR-4 signalling 18 .
Likewise, no alterations in the mRNA expression of the cytokines studied were observed after poly-IC treatment (data not shown), indicating that also TLR-3 did not contribute to eRNAmediated cytokine induction. Thus, eRNA functions as a powerful inducer of inflammatory cytokine responses in macrophages, independent of TLR-2, TLR-3 and TLR-4 signaling.
eRNA serves as damage marker in experimental atherosclerosis
To assess the functional role of eRNA in lesion growth, a model of injury-induced, accelerated atherosclerosis was employed. After injury, apolipoprotein E-deficient (apoE , we e ca ca an co on n nclu lu ude de de t t tha ha hat t eR eR eRNA NA NA d does s s n n not e e en ng gag g ge e in in T TLR LR L --2 -2 and nd d TLR LR LR-4 -4 -4 s sig ign na nall ll l in in ing 18 18 18 .
Li Like ke kewi wi wise se, , , no no no a alt lte e era at atio ions ns i in n th h he e mR mR mRNA NA N e exp xp xpre re ress s sio io ion n n o of f th h he e cy cy cyt t toki ki kine ne es s st st stud ud die ed d w we were re re o obs bs bse erv v ved d d af af ft t ter r r poly-IC treatm tm men en e t t t (d (d (dat at ta a no no ot t t sh sh show ow wn) n) n , , in indi di d ca ca cati ti ting ng ng t tha ha h t t t al al a so so o T T TLR LR LR-3 -3 3 d d did id n n not ot ot c c con on ontr tr t ib ib but ut ute e e to to to e eRNA-5%) 4, 8 . We therefore determined the source of eRNA by analyzing the expression of specific mRNA species, indicative of the originating cell type. qPCR analysis revealed that both Cd31 mRNA, employed as a marker for endothelial cells, as well as SMA mRNA as a marker for SMC, were increased in plasma at day 1 but not immediately after injury ( Figure 4B ). These data indicate that endothelial cells and SMC release eRNA into the extracellular space during and after arterial injury.
Notably, eRNA was increased in supernatants of SMC in a time-dependent manner when cells were treated with TNF- (Figure 4C ), indicating that SMC may release eRNA also during cell activation.
Treatment of apoE -/-mice with RNase1 diminishes experimental atherosclerosis
In order to investigate if eRNA directly or indirectly contributes to neointima formation after arterial injury, apoE -/-mice fed a HFD and treated with RNase1 or vehicle (PBS) alone were subjected to wire-induced injury of the common carotid artery. RNase activity was markedly elevated in RNase1-treated mice, but not in control mice throughout the 3 week study period (Supplemental Figure 2) . Moreover, RNase1 treatment inhibited the increase in eRNA ( Figure   4A ), and similarly diminished Cd31 and SMA mRNA appearance in plasma after injury compared to control-treated apoE -/-mice ( Figure 4B ), confirming efficiency of the treatment.
Neointima formation was assessed at one and three weeks after injury, and revealed a trend towards reduced neointima formation at one week after injury and a significant reduction performed at 1 week after injury, was reduced in RNase1-treated mice ( Figure 6H,I ). These data de demo mo mon ns nst trat at ate e e t t that at t t th he he retardation in plaque growth th th in n nduced by RN Nas a a e-1 1 tr tr tre eatment was associated 
Discussion
In the present study the multifunctional eRNA/RNase system was characterized for its contribution to chronic vascular disease as it relates to the progression of atherosclerotic lesion formation in two established mouse models. Our data indicate that (i) in Ldlr -/-mice fed a HFD, eRNA accumulates in atherosclerotic plaques in a time-dependent manner, can be released from activated cells, and is increased in plasma of apoE -/-mice after arterial injury; (ii) conversely, a biphasic characteristic for plasma RNase activity was observed with an increase soon after the initiation of HFD, and a decline to levels below baseline during progressive plaque growth; (iii) administration. Notably, leukocyte adhesion to injured artery segments was subs st t tant nt ntia iall ll ly y y re re redu du duce c d Recently, it was revealed that eRNA not only promotes the adhesion and transmigration of leukcoytes in the murine cremaster muscle vasculature, but that it also induces the expression of ICAM-1 in endothelial cells in vitro 7 . Similarly, we here observed in increase in adhesion molecules ICAM-1, VCAM-1, P-Selectin and CCL2 in SMC, which may likewise contribute to nflammatory cytokines was demonstrated: This is in line with a shift in macroph ph hag ag ge e po po pola la lari ri riza za z ti tion wh wh hil il i e e e RN RN R as as ase1 e1 e t tre re ea at atme me ent nt t s sig i ni ni nifi fi ica ca cant nt ntl ly ly r r red ed duc uc uced ed ed t t the he heir r ex ex xpr pr pres es ess si sion on on l le ev evel el els s s c c com mp mpa ar ared ed ed t to o o c c cont nt tro o ols ls. . In In essence, the a app pp ppea ea ara ra ranc nc ce e e of f f e e eRN RN RNA A A in in n t the he he d d dis is isea ea ease se sed d d ti ti iss ss sue ue m m may ay ay t thu hu hus s s be be e c c con on onsi si side de dere re ed d d as as as a a an n n alarm monocyte adhesion to activated SMC as well as to leucocyte recruitment in carotid arteries after injury 22 . Importantly, and in line with a pro-inflammatory function of eRNA, our findings show that the systemic treatment with RNase1 reduced adhesion molecule expression, inhibited leukocyte adhesion and reduced arterial macrophage accumulation and neointimal plaque formation after injury in carotid arteries of apoE -/-mice in vivo.
eRNA was also demonstrated to mediate vascular permeability via the mobilization/stabilization and direct binding to vascular endothelial growth factor 5 . Enhanced vascular endothelial growth factor signaling induced by eRNA may in addition promote monocyte adhesion and plaque expansion 23 .
In addition, eRNA was shown to act as a pro-thrombotic cofactor. Accordingly, systemic treatment with RNase1 rescued mice from thrombotic occlusion of the carotid artery in a model of arterial thrombosis 3 , and reduced cerebral edema and infarction size in acute stroke 9 .
Neointimal hyperplasia after arterial injury is characterized by endothelial denudation, exposure of extracellular matrix, and adhesion of activated platelets, which all contribute to inflammatory leukocyte recruitment and neointima formation after injury 24 . By contributing to platelet accumulation at the site of injury, eRNA may thus in addition promote injury-induced leukocyte adhesion and neointimal hyperplasia.
The underlying pathogenetic mechanisms of eRNA as a pro-inflammatory mediator may thus involve both direct and indirect signaling pathways. Our findings thus indicate that eRNA serves as an important inflammatory mediator after vascular injury, identifying extracellular ribonucleic acids as a new target for the treatment of inflammation during vascular remodeling.
Together, the present study provides novel experimental evidence for the multifunctional properties of self-eRNA as an important trigger of different inflammatory processes that fuel In addition, eRNA was shown to act as a pro-thrombotic cofactor. Accord rd din ing gl g y, y, y, s s sys ys yste te tem mic reatment with RNase1 rescued mice from thrombotic occlusion of the carotid artery in a model of f a a art rt rter er eri ia ial l l th th thr ro omb mb bo os osis 3 , and reduced cerebral ede e ema ma ma and infarctio on n n size ze e i i in n n acute stroke 9 .
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15. Neu C, Sedlag A, Bayer C, Forster S, Crauwels P, Niess JH, van Zandbergen G, Frascaroli G, Riedel CU. Cd14-dependent monocyte isolation enhances phagocytosis of listeria monocytogenes by proinflammatory, gm-csf-derived macrophages. PloS one. 2013;8:e66898. 
SUPPLEMENTAL MATERIAL Supplemental Methods
Arterial wire-induced injury
Wild-type and Ldlr 
Immunohistochemistry
For evaluation of neointima formation, mice were sacrificed at indicated time points, in situ fixed with 4 % paraformaldehyde, and carotid arteries were excised and embedded in paraffin.
Neointimal and medial areas were quantified in serial sections (5 µm; 10 per mouse) within 500 µm from the bifurcation by Movat's pentachrome staining and planimetry of the areas within external elastic lamina, internal elastic lamina, or lumen (Diskus software, Hilgers).
Adjacent sections were used to assess plaque cellular content by immunofluorescence staining of macrophages and SMCs by mAb staining for Mac2 (rat anti-mouse, Santa Cruz) and α-smooth muscle actin (mouse anti-human, Santa Cruz), respectively. Briefly, slides were blocked with 1% bovine serum albumin (Sigma Aldrich), incubated with primary antibody overnight at 4°C, and secondary detection performed using the relevant Alexafluor 488-conjugated antibody (Molecular Probes, Life Technologies, Germany). Sections were counterstained with DAPI (1µg/mL; Merck, Darmstadt Germany) for visualisation of cell nuclei, then coverslipped using Vectorshield mounting medium (Vector Laboratories, Burlingame, USA). Images were recorded using a Leica DM-RXE fluorescence microscope, and quantified using Diskus software.
To determine the distribution of eRNA in atherosclerotic lesions, mice were sacrificed at indicated time points and perfused via the left ventricle with 10 ml PBS containing 1 mM EDTA and 30 ml fixative (PBS, 4% paraformaldehyde and 5% sucrose), and the atherosclerotic lesions were analyzed in the heart aortic valve as described previously for nuclei detection. Specimens were visualized using the confocal NIKON-microscope ECLIPSE TE200-E (Nikon, Düsseldorf, Germany), sections were taken through the tissue at 0.25 µm intervals, and analyzed by image acquisition software EZ-C1 Goldversion 3.8.
Confocal microscopy and quantification of RNA
Cryosections (5 μm thick) of aortic sinus from Ldlr -/-mice were air dried and fixed with 4% paraformaldehyde and then incubated with 1% bovine serum albumin for 30 min to block non-specific binding sites. After rinsing in PBS, the samples were incubated 2 h at room temperature with primary antibodies against smooth muscle -actin TRITC-labeled (Sigma).
After repeated washes with PBS, the tissue sections were incubated with SYTO® RNASelect™ dye (Invitrogen) used for RNA localization. Nuclei were visualized with DAPI (Molecular Probes). Tissue sections were examined by laser scanning confocal microscopy (Leica TCS SP2), and confocal optical sections were taken using a Leica x63/1.32 objective lens. Each recorded image was taken using multi-channel scanning and consisted of 1024 x 1024 pixels. To improve image quality and to obtain a high signal to noise ratio, each image from the series was signal-averaged and was deconvoluted using AutoQuant X2 software (Bitplane, Zürich, Switzerland). For three-dimensional image reconstructions, an Imaris 6.3.1 multichannel image processing software (Bitplane) was used.
For quantification of the eRNA, all tissue samples were simultaneously immunolabeled under identical conditions of fixation and dilutions of primary and secondary antibodies. Ten randomly chosen fields of vision were quantified using three-dimensional "Quantification"
and "VoxelShop" options of Imaris 6.3.1 (Bitplane). The area of specific labeling for eRNA was calculated as arbitrary fluorescent units of positive labelling, each for the media area or neointima area, as previously described. 2 
Intravital imaging
For intravital microscopy, 0.05% rhodamine-G (Molecular Probes) was administered i.v. to apoE -/-mice fed an atherogenic diet and treated with RNase or vehicle (PBS) 1 day after injury. Carotid arteries were exposed in anesthetized mice (100 mg/kg bodyweight ketamine and 10 mg/kg bodyweight xylazine). Arrest of labeled leukocytes was visualized by epifluorescence microscopy (Olympus BX51, 20x water immersion), and recorded using a digital camera (Hamamatsu EM-CCD, C9100) and analysed using Cell-R software (Olympus).
Isolation of extracellular RNA and real time PCR analysis
DNA-free total RNA was extracted from plasma of mice or, from supernatants of SMC or SMC using Zymo RNA MicroPrep kit (Zymo Research) omitting a lysis step and with an additional DNase digestion step. Total RNA (10 ng) was reverse-transcribed at 37°C for 1 h. Human coronary artery SMC (Promocell) and MonoMac6 cells were maintained as described 3, 4 . MonoMac6 cell adhesion to SMC was analyzed in parallel wall flow-chambers 3 .
Confluent SMC were activated with TNF- (50 ng/ml) in the absence or presence of RNase1 
Viability assay
After treating SMC or MM6 with RNase1 (10 µg/ml) for 30 min or 16 h, respectively, viability assays were performed by using the fluorescent CellTiter-Blue ® cell viability assay (Promega) according to the manufacturer's instructions.
Statistics
Data were analyzed by unpaired Student t tests, and if more than 2 groups were compared by ANOVA 1-way analysis of variance followed by Tukey's or Dunnett's multiple comparison post tests. Differences with p<0.05 were considered to be statistically significant. Analyses for Figures 5A-C, and Figure 7B were performed using two tailed t-tests. Analyses for Figure   2L and 4A were performed using a one-way ANOVA followed by Tukey multiple comparison test. Analysis for Figure 2A , 3A-D, 4B-C, 6A-G, 7B and Supplemental Figure 1 and 3 were performed using a one-way ANOVA followed by Dunnett's multiple comparison test. Statistical analyses were performed using Graph Pad Prism 6.0.
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